Liqiang Xi
Staff Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
The primary objective in multiply relapsed hairy cell leukemia and variant (HCL/HCLv) was to determine whether pentostatin-rituximab (DCFR) and bendamustine-rituximab (BR) each achieve an overall response rate (ORR) exceeding that historically achieved by rituximab alone (∼40%) in favor of 65%. Prospective data were unreported for either regimen. Fifty-six patients received 6 28-day cycles of rituximab (375 mg/m2, days 1 and 15) with either bendamustine (90 mg/m2, days 1 and 2) or pentostatin (4 mg/m2, days 1 and 15). Eligibility required ≥2 purine analogs, or 1 purine analog plus rituximab for response of <1 year to the initial purine analog. Although patients were assigned to either regimen through randomization to increase homogeneity of the 2 treatment groups, the DCFR arm had fewer previous purine analogs (P = .021) and lower baseline marrow HCL/HCLv infiltration (P = .013). ORRs for DCFR and BR were 93% (95% confidence intervals [CI], 83-102) and 86%, (95% CI, 73-99), respectively, exceeding 40% (P< .0001) for each group. Rates for complete remission (CR) and minimal residual disease-free CR and median progression-free survival (141 vs 50 months; HR, 0.63; 95% CI, 0.32-1.25) numerically favored DCFR, but that arm was significantly enriched with less previous purine analogs and marrow infiltration, each of which was associated post hoc with better response. Post hoc subgroup analysis, particularly for 41 patients with classic HCL, suggested any superiority of DCFR vs BR might apply to patients with more favorable disease. DCFR and BR were highly effective in multiply relapsed HCL/HCLv. Possible DCFR superiority was hypothesis-generating, given uneven baseline risks and trial design. This trial was registered at www.clinicaltrials.gov as #NCT01059786.
Year:
2026
Year:
2025
We found 20 patients with an immunophenotype consistent with classic hairy cell leukemia and BRAF mutations other than just V600E. Fourteen had 1 non-V600E BRAF mutation and 6 had V600E with 1 (n = 5) or 2 (n = 1) non-V600E BRAF comutations. This study was registered at https://clinicaltrials.gov as #NCT01087333.
Year:
2025
Summary and list of detected and reported alterations by alteration type (CNV, SNV/Indel) and assay (both assays, Central Lab (CL) or Assay H only, Pilot Lab only). For both detected and reported variants, positive percent agreement (PPA) with Pilot Lab and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.
Year:
2025
Scatter plots of continuous copy number results obtained from Central Lab (CL) or assay H and Designated Lab (DL) assay. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is for variants detected by both assays but not reported by at least one assay, and orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.
Year:
2025
Purpose: NCI selected a network of Clinical Laboratory Improvement Amendments–certified laboratories performing routine next-generation sequencing (NGS) tumor testing to identify patients for the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) trial. This large network provided a unique opportunity to compare variant detection and reporting between a wide range of testing platforms. Experimental Design: Twenty-eight NGS assays from 26 laboratories within the NCI-MATCH Network, including the NCI-MATCH central laboratory (CL) and 11 commercial and 14 academic designated laboratories (DL), were used for this study. DNA from eight cell lines and two clinical samples were sequenced. Pairwise comparisons in variant detection and reporting between each DL and CL were performed for single-nucleotide variant, insertion and deletion, and copy-number variant classes. Results: We observed high concordance in variant detection between CL and DL for single-nucleotide variants and insertions and deletions [average positive agreement (APA) > 95.4% for all pairwise comparisons] but lower concordance for variant reporting after analysis pipeline filtering. We observed much higher agreement between CL and assays using amplification as the target enrichment method (84.2% 82%) except between CL and two assays (APA = 76.9% and 71.4%) due to differences in estimation of copy numbers. Notably, for all variants, differences in variant interpretation also contributed to reporting discrepancies. Conclusions: This study indicates that different NGS tumor profiling tests currently in widespread clinical use achieve high concordance between assays in variant detection. For variant reporting, observed discrepancies are mainly introduced during the bioinformatic analysis.
Year:
2025
Summary of detected and reported CNV alterations by assay (both assays, Central Lab (CL) or assay H only, Designated Lab (DL) assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.
Year:
2025
Summary of detected and reported CNV alterations by assay (both assays, Central Lab (CL) or assay H only, Designated Lab (DL) assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated. Cytogenetics results for all concordance study samples and gene amplification measurements using different techniques: NGS, ddPCR, microarray and FISH
Year:
2025
A, Scatter plot of continuous VAF results between Central Lab (CL) or assay H and Pilot Lab. B, Scatter plot of continuous CN results. The large plot focuses on copy numbers up to 50, while the small inset shows the full range of CNV. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is detected but not reported by Pilot Lab, while orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.
Year:
2025
Each worksheet shows all variants reported by a given Designated Laboratory, including those that are outside of the overlap region between the Central Assay and the Designated Laboratory Assay
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Collaborators (27)
Jean Donadieu
MD Ph D
Assistance Publique - Hôpitaux de Paris
Hao-Wei Wang
Head, FLOW CYTOMETRY LABORATORY
National Cancer Institute
Wenjuan Zhang
Assistant Professor
Cedars-Sinai Medical Center
Noah Brown
Assistant Professor
University of Michigan Hospital
Alice Chen
Head, Early Clinical Trial Development Program
National Cancer Institute
Markku Miettinen
Senior Clinician, Head of Surgical Pathology
National Institutes of Health
Irene Gullo
Professor Auxiliar Convidado
University of Porto
Lisa McShane
Associate Director, Division of Cancer Treatment & Diagnosis
National Cancer Institute
Szabolcs Szelinger
Research Assistant Professor
Translational Genomics Research Institute
Manoj Tyagi
Head of Bioinformatics Unit
National Institutes of Health
Peining Li
Professor
Yale University School of Medicine
Parth Anil Desai
Assistant Professor/Clinical Investigator
Fox Chase Cancer Center
Christopher William Schultz
Assistant Professor
Temple University
Elaine Jaffe
Head, Hematopathology Section
National Cancer Institute
maxime battistella
Assistant professor
Université Paris Diderot
Jean-François Emile
Université de Versailles Saint-Quentin-en-Yvelines
Michelle Afkhami, MD
Chief and Professor, Division of Molecular Pathology and Therapy Biomarkers
City of Hope
Mahesh Mansukhani
Professor
Columbia University Irving Medical Center
Neal Lindeman
Vice Chair, Molecular Pathology and Laboratory Medicine
Weill Cornell Medicine
RAVINDRA KOLHE
Augusta University
SHUBHANK GOYAL
The University of Texas Rio Grande Valley
Eric Konnick
Associate Professor
University of Washington
Svetlana Pack
Staff Scientist
National Institutes of Health
Jeremy Davis
Professor and Chief, Division of Surgical Oncology
University of Maryland School of Medicine
Zenta Walther
Associate Professor
Yale University School of Medicine
Theo Heller
National Institutes of Health
William D Figg
Senior Investigator, Lab Chief, Associate Director
National Institutes of Health
Make your next move.
Prepare your application
Review drafts before you send them.